Represented Swiftmerge Acquisition Corp. in its merger with HDL Therapeutics

Represented Swiftmerge Acquisition Corp. in its merger agreement with HDL Therapeutics, a a privately held commercial stage biotech company with an FDA-approved cardiovascular therapy the Plasma Delipidation System (PDS-2™ System) for reducing coronary atheroma in patients with homozygous familial hypercholesterolemia (HoFH).